Idiopathic pulmonary fibrosis is a chronic progressive disease with unknown etiology. The prognosis of idiopathic pulmonary fibrosis is very poor, indeed if untreated, it can lead to death 2-5 years after the diagnosis.
In this disease, the lungs become scarred with increased breathing difficulties making necessary the use of therapies to help the patients breathe and reduce the lung damage. Moreover, patients with idiopathic pulmonary fibrosis are at increased risk for severe COVID-19 and cancer.
As the etiology is unknown and there is no current cure for idiopathic pulmonary fibrosis, research is concentrated on the management of the patients, both in hospital and outpatients, to find the better treatment to increase the favorability of the prognosis. Due to the severity of the diseases, there is an urgency to find novel biomarkers for the diagnosis, treatment, and prognosis and to identify the risk factors for idiopathic pulmonary fibrosis.
With this Research Topic we would like to collect manuscripts investigating the following subjects:
- Recent advances for the treatment and therapies of idiopathic pulmonary fibrosis
- Antifibrotic treatment
- Management of idiopathic pulmonary fibrosis patients
- Risk factors for pulmonary fibrosis, such as genetics, age, gender, and lifestyle
Idiopathic pulmonary fibrosis is a chronic progressive disease with unknown etiology. The prognosis of idiopathic pulmonary fibrosis is very poor, indeed if untreated, it can lead to death 2-5 years after the diagnosis.
In this disease, the lungs become scarred with increased breathing difficulties making necessary the use of therapies to help the patients breathe and reduce the lung damage. Moreover, patients with idiopathic pulmonary fibrosis are at increased risk for severe COVID-19 and cancer.
As the etiology is unknown and there is no current cure for idiopathic pulmonary fibrosis, research is concentrated on the management of the patients, both in hospital and outpatients, to find the better treatment to increase the favorability of the prognosis. Due to the severity of the diseases, there is an urgency to find novel biomarkers for the diagnosis, treatment, and prognosis and to identify the risk factors for idiopathic pulmonary fibrosis.
With this Research Topic we would like to collect manuscripts investigating the following subjects:
- Recent advances for the treatment and therapies of idiopathic pulmonary fibrosis
- Antifibrotic treatment
- Management of idiopathic pulmonary fibrosis patients
- Risk factors for pulmonary fibrosis, such as genetics, age, gender, and lifestyle
